EGFR and breast carcinoma: Recent advancement in drug discovery has led to the development of several therapeutic approaches for the treatment of breast cancer such as monoclonal antibodies (cetuximab, Panitumumab), antisense oligonucleotides (Phosphorothioate oligodeoxynucleotides), and antibody‐based immuno‐conjugates (40H3‐Deruxtecan, IgG1‐Tesirine, IMGN289) apart from the EGFR‐TKIs (erlotinib and gefitinib), which act via down‐regulating the various signaling pathways.37, 38, 39, 40